RIEU, JEAN-PIERRE,IMBERT, THIERRY,PATOISEAU, JEAN-FRANCOIS,LERICHE, LUDOVIC,SOKOLOFF, PIERRE
申请号：
NZ59793010
公开号：
NZ597930A
申请日:
2010.08.31
申请国别(地区):
NZ
年份:
2013
代理人:
摘要：
Abstract 597930 The present disclosure relates to chromone derivatives, their preparation, their pharmaceutical compositions and their application as D3 dopaminergic ligands as a medicament for disorders of the central nervous system. Conditions that may be treated using the disclosed compounds include: Parkinsons disease, psychosis, schizophrenia, dyskinesias associated with Parkinsons disease,cognitive deficiency optionally associated with age or with Alzheimers disease, mood disorder, essential tremor, anxiety, depression, bipolar disorder, sexual impotence, premature ejaculation, alcoholism and nicotine addiction. Specifically disclosed compounds include but are not limited to: 6,7-dimethoxy-3-{ 4-[4-(2-methoxyphenyl)-piperazin-1-yl]-butyl} -chromen-4-one 5-{ 4-[4-(6,7-dimethoxy-4-oxo-4H-chromen-3-yl)-butyl]-piperazin-1-yl} -1H-quinolin-2-one N-(3-{ 4-[4-(6,7-dimethoxy-4-oxo-4H-chromen-3-yl)-butyl]-piperazin-1-yl} -phenyl)-acetamide 2-methoxyethanesulfonic acid (3-{ 4-[4-(8-oxo-8H-[1,3]dioxolo[4,5-g]chromen-7-yl)-butyl]-piperazin-1-yl} -phenyl)-amide And 4-{ 4-[4-(6,7-dimethoxy-4-oxo-4H-chromen-3-yl)-butyl]-piperazin-1-yl} -1,3-dihydrobenzimidazol-2-one.
